Prevention and management of lung infections with thymosin alpha1 in critical patients with tracheotomy.
- Author:
Deng-peng HUANG
1
;
Ming YANG
;
Wei-ping PENG
;
Xiao-she CHEN
;
Zhong-qing CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adjuvants, Immunologic; therapeutic use; Adolescent; Adult; Aged; Brain Injuries; drug therapy; surgery; Cerebral Infarction; drug therapy; Critical Illness; Female; Humans; Intensive Care Units; Male; Middle Aged; Pneumonia; prevention & control; Thymosin; analogs & derivatives; therapeutic use; Tracheotomy; adverse effects
- From: Journal of Southern Medical University 2006;26(1):128-129
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the preventive and therapeutic effect of thymosin alpha(1) on lung infections in critical patients with tracheotomy.
METHODSForty-two patients were randomly divided into treatment group and control group to receive daily subcutaneous thymosin injection at 11.6 mg and saline of 2 ml for 7 days, respectively.
RESULTSCompared with the control group, the infection rate, white blood cell count, C-reactive protein, tumor necrosis factor-alpha and interleukiu-6 were significantly lower in the treatment group.
CONCLUSIONThymosin alpha(1) can be effective for prevention and treatment of lung infections in critical patients with tracheotomy and may improve the patients' immunity and prognosis.
